Pancreatic Cancer

The FDA approved olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma.

The PARP inhibitor was recommended as a first-line maintenance monotherapy for patients with germline BRCA-mutated metastatic pancreatic cancer.

Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.

MCLA-128 showed radiological and clinical responses in patients with certain types of cancer who harbored neuregulin 1 gene fusions.

The worldwide incidence, and death toll, of colorectal and pancreatic cancers have sharply increased since 1990, according to the results of a new study.

Treatment with 9-ING-41 significantly increased pancreatic tumor cell killing when combined with chemotherapy in pre-clinical trials.

Researchers examine patterns of recurrence after resection of pancreatic ductal adenocarcinoma.  

Researchers believe that previous findings about coffee consumption’s possible link to an increased risk of pancreatic cancer come from confounding factors that were not accounted for, such as smoking.

An imaging-based biomarker may offer a way to personalize treatment for pancreatic ductal adenocarcinoma.

A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.

The U.S. Preventive Services Task Force released a new review of the benefits and harms of imaging-based screening for pancreatic cancer.

A combination of durvalumab and tremelimumab was tested on patients with metastatic pancreatic ductal adenocarcinoma.

The United States Preventive Services Task Force issued a statement reaffirming its 2004 recommendation against screening for pancreatic cancer in asymptomatic adults.

Negative trial findings suggest immune checkpoint inhibitors may not be the best type of immunotherapy to treat pancreatic cancer.

Data presented at ASCO 2019 suggest that a PARP inhibitor yields a clinically meaningful improvement in PFS in metastatic pancreatic cancer patients with a germline BRCA mutation.

Cancer Network spoke with Mark H. O'Hara, MD, about the safety and efficacy of APX005M in combination with standard chemotherapy with or without nivolumab.

Investigators evaluated whether patients with pancreatic ductal adenocarcinoma benefit from adjuvant therapy after surgery if the tumor is smaller than 1 cm.

Radioguided surgery using gallium 68 dota peptides offers a highly sensitive method for detecting neuroendocrine tumors.

Study shows that ctDNA levels measured by targeted deep sequencing sensitively indicate the presence of cancer.

A team of Texas-based oncologists says their preclinical study results “demonstrate that IGF-1R and FOXC1 seem to positively regulate each other.”

“Tumor cell–intrinsic factors shape the tumor immune microenvironment and influence the outcome of immunotherapy,” the lead study author concluded.

When MUC4/X-overexpressing pancreatic cancer cells were transplanted into mice, tumors grew aggressively, with significant metastasis to liver and peritoneum.

In PREOPANC, the 2-year survival rate was significantly higher for patients who received neoadjuvant chemoradiotherapy vs standard care.

Compared with gemcitabine, mFOLFIRINOX improved outcomes for all endpoints when used in the adjuvant setting.

Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.

The US Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera) for the treatment of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults.

ASCO clinical practice guidelines recommend resection followed by treatment with gemcitabine and capecitabine as the standard of care; however, neoadjuvant therapy is also considered an appropriate alternative.

Neoadjuvant therapy is an attractive approach with the promise of clinical benefit for patients with surgically resectable pancreatic cancer. However, clinical trial results in support of this approach remain unconvincing.

Researchers are proposing the consideration of expanding criteria for liver debulking in pancreatic neuroendocrine tumors to include a threshold of greater than 70% debulking, intermediate grade tumors, positive margins, parenchyma-sparing resections, and extrahepatic metastases.